• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association 1994.
  • 2
    Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; II: 888891.
  • 3
    Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatiliy of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997; 82: 234238.
  • 4
    Nemeroff C, Widerlov E, Bissette G. Elevated cerebrospinal fluid concentrations of corticotropin-releasing factor-like immunoreactivity in major depression. Science. 1984; 226: 13421344.
  • 5
    Holsboer F, von Bardeleben U, Wiedemann K, Muller OA, Stalla GK. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry. 1987; 22: 228234.
  • 6
    Heuser I, Yassouridis A, Holsboer F. The combined dexamethason/CRH test: a refined laboratory test for psychiatric disorder. J Psychiatr Res. 1994; 28: 341356.
  • 7
    Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry. 1999; 156: 949951.
  • 8
    Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res. 2001; 35: 8394.
  • 9
    Young EA, Altemus M, Lopez JF, et al. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology. 2004; 29: 11981204.
  • 10
    Danzer R, Bluthke RM, Kent S, Goddall G. Behavioral effects of cytokines: an insight into mechanisms of sickness behavior. Methods Neurosci. 1993; 17: 130144.
  • 11
    Sluzewska A, Rybakowski J, Bosamans E, et al. Indicators of immune activation in major depression. Psychiatry Res. 1996; 64: 161167.
  • 12
    Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma Interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001; 158: 12521257.
  • 13
    Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998; 128: 127137.
  • 14
    Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res. 2000; 10: 237241.
  • 15
    Breuninger LM, Dempsey WL, Uhl J, Murasko DM. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 1993; 69: 205214.
  • 16
    Papanicolaou DA, Petrides JS, Tsigos C, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 1996; 271: E601E605.
  • 17
    Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology. 1997; 65: 7990.
  • 18
    Smith PC, Hobisch A, Lin Dl, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001; 12: 3340.
  • 19
    Scambia G, Testa U, Panici PB, et al. Interleukin-6 and serum levels in patients with gynaecological tumors. Int J Cancer. 1994; 57: 318323.
  • 20
    Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martionez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991; 164: 10381043.
  • 21
    Endicott J. Measurement of depression in patients with cancer. Cancer. 1984; 53: 22432248.
  • 22
    Massie MJ. Depression. In: HollandJC, RowlandJH, editors. Handbook of Psychooncology: Psychological Care of the Patient with Cancer. New York: Oxford University Press; 1989: 283290.
  • 23
    Derogatis LR, Morrow GR, Fetting J. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983; 249: 751757.
  • 24
    Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med. 1977; 39: 264276.
  • 25
    Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004; 32: 5771.
  • 26
    Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949: 191.
  • 27
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders. Research version, patient ed. New York: Biometrics Research, New York State Psychiatric Institute; 1999.
  • 28
    Moorey S, Greer S, Watson M, et al. The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry. 1991; 158: 255259.
  • 29
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361370.
  • 30
    Bisson JI, Chubb HL, Bennet S, et al. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int. 2002; 90: 5661.
  • 31
    Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000; 48: 379391.
  • 32
    Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systemic review of the literature with meta-analysis. Psychosom Med. 2002; 64: 5260.
  • 33
    Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biological variables with depression in older people living in the community. J Am Geriatr Soc. 1999; 47: 611.
  • 34
    Constanzo ES, Lutgendorf S, Sood A, Anderson B, Sorosky J, Lubaroff D. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005; 104: 305313.
  • 35
    Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressive patients in Japan. Neuropsychobiology. 2001; 43: 5962.
  • 36
    Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993; 77: 16901694.
  • 37
    Besedovsky HO, Del Rey A. Immune-neuro-endocrine interaction: facts and hypotheses. Endocr Rev. 1996; 17: 64102.
  • 38
    Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999; 461: 107116.
  • 39
    Maes M, Bosmans E, Dejongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997; 9: 853858.
  • 40
    Peteet J, Tay V, Choen G, MacIntyre J. Pain characteristics and treatment in an outpatient cancer population. Cancer. 1986; 57: 12591265.
  • 41
    Gregory RJ, Jimerson DC, Walton BE, Daley J, Paulsen RH. Pharmacotherapy of depression in the medically ill: directions for future research. Gen Hosp Psychiatry. 1992; 14: 3642.
  • 42
    Kathol RG, Mutigi A, Williams J, Clamon G, Noyes R. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990; 147: 10211024.
  • 43
    Cohen-Cole SA, Brown FW, McDaniel JS. Diagnostic assessment of depression in the medically ill. In: StoudemireA, FogelB, editors. Psychiatric Care of the Medical Patient. New York: Oxford University Press; 1993: 5370.
  • 44
    Harter M, Woll S, Wunsch A, Bengel J, Reuter K. Screening for mental disorders in cancer, cardiovascular and musculoskeletal disease. Soc Psychiatry Psychiatr Epidemiol. 2006; 41: 5662.
  • 45
    Bjelland I, Dahl A, Haug T, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychiat Res. 2002; 52: 6977.
  • 46
    Costa E, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985; 72: 8592.
  • 47
    Stoudemire A, Thompson TL. Medication non-compliance: systematic approaches to evaluation and intervention. Gen Hosp Psychiatry. 1983; 5: 233239.
  • 48
    Koenig HG, Shelp F, Goli V, Cohen HJ, Blazer DG. Survival and healthcare utilization in elderly medical inpatients with major depression. J Am Geriatr Soc. 1989; 37: 599606.